Immunosuppressive drug therapy for rheumatic disease

Area of Science:

• Immunology
• Rheumatology
• Nephrology

Background:

• Cyclophosphamide and cyclosporine are key immunosuppressants for autoimmune diseases.
• Their efficacy and long-term effects require ongoing investigation.

Purpose of the Study:

• To evaluate cyclophosphamide regimens for lupus nephritis and Wegener's granulomatosis.
• To assess cyclosporine's role and safety in rheumatoid arthritis and scleritis.
• To explore cytarabine's potential in rheumatoid arthritis.

Main Methods:

• Comparative trials of oral and intravenous cyclophosphamide for lupus nephritis.
• Analysis of long-term outcomes in Wegener's granulomatosis patients treated with cyclophosphamide.
• Observational studies on cyclosporine in rheumatoid arthritis and necrotizing scleritis.
• Assessment of renal function and nephropathy in patients receiving cyclosporine.

Main Results:

• Long-term intravenous cyclophosphamide outperformed other regimens for lupus nephritis.
• Oral cyclophosphamide was less effective for lupus nephritis with abnormal creatinine.
• Wegener's granulomatosis patients showed high rates of cancer and recurrence post-cyclophosphamide.
• Cyclosporine use in rheumatoid arthritis correlated with nephropathy; NSAID co-administration worsened renal function short-term.
• Cytarabine showed some benefit in rheumatoid arthritis.

Conclusions:

• Long-term intravenous cyclophosphamide offers superior outcomes for lupus nephritis.
• Cyclophosphamide treatment for Wegener's granulomatosis necessitates vigilant long-term monitoring for malignancy and recurrence.
• Cyclosporine requires careful dosing and monitoring for nephrotoxicity, especially when combined with NSAIDs.